Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


29.01.2018

4 BJU Int
1 Cancer
1 Cancer Res
4 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
3 J Nucl Med
8 J Urol
2 Nat Rev Urol
1 PLoS One
7 Prostate
1 Radiology
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. RUTLEDGE AB, McLeod N, Mehan N, Regan TW, et al
    A clinician-centred program for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14144.
    PubMed     Text format     Abstract available

  2. WALLIS CJD, Satkunasivam R, Bhindi B
    Selecting patients for prostate cancer treatment: the role of comorbidity.
    BJU Int. 2018;121:164-165.
    PubMed     Text format    

  3. SOLIGO M, Sharma V, Karnes RJ
    Is it time for a more 'proactive' approach to metastatic prostate cancer?
    BJU Int. 2018;121:167-168.
    PubMed     Text format    

  4. ABDEL-RAHMAN O, Cheung WY
    External Validation Of The Prostascore Model Among Metastatic Hormone-Sensitive Prostate Cancer Patients Recruited In The CHAARTED Study.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14138.
    PubMed     Text format     Abstract available


    Cancer

  5. KAUR D, Ulloa-Perez E, Gulati R, Etzioni R, et al
    Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
    Cancer. 2018 Jan 25. doi: 10.1002/cncr.31253.
    PubMed     Text format     Abstract available


    Cancer Res

  6. MCCLINCH K, A Avelar R, Callejas D, Izadmehr S, et al
    Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0123.
    PubMed     Text format     Abstract available


    Eur Urol

  7. MA TM, Tosoian JJ, Schaeffer EM, Landis P, et al
    The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Eur Urol. 2017;71:174-180.
    PubMed     Text format     Abstract available

  8. GRANDE P, Di Pierro GB, Mordasini L, Ferrari M, et al
    Prospective Randomized Trial Comparing Titanium Clips to Bipolar Coagulation in Sealing Lymphatic Vessels During Pelvic Lymph Node Dissection at the Time of Robot-assisted Radical Prostatectomy.
    Eur Urol. 2017;71:155-158.
    PubMed     Text format     Abstract available

  9. RAUSCHER I, Duwel C, Haller B, Rischpler C, et al
    Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Eur Urol. 2018 Jan 18. pii: S0302-2838(18)30010.
    PubMed     Text format     Abstract available

  10. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jan 17. pii: S0302-2838(18)30005.
    PubMed     Text format     Abstract available


    Int J Cancer

  11. TOMIC K, Ventimiglia E, Robinson D, Haggstrom C, et al
    Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31272.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  12. DORTH JA, Lee WR, Chino J, Abouassaly R, et al
    Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018;100:383-390.
    PubMed     Text format     Abstract available


    J Clin Oncol

  13. HORIGUCHI M, Uno H, Wei LJ
    Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2017759829. doi: 10.1200/JCO.2017.75.9829.
    PubMed     Text format    

  14. ABIDA W, Sawyers CL
    Targeting DNA Repair in Prostate Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017766592. doi: 10.1200/JCO.2017.76.6592.
    PubMed     Text format    


    J Nucl Med

  15. ROWE SP, Pomper MG, Gorin MA
    Molecular Imaging of Prostate Cancer: Choosing the Right Agent.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.206318. doi: 10.2967/jnumed.117.206318.
    PubMed     Text format    

  16. RATHKE H, Afshar-Oromieh A, Giesel FL, Kremer C, et al
    Intra-individual comparison of Tc-99m-MDP bone scan and the PSMA-ligand Tc-99m-MIP-1427 in patients with osseous metastasized prostate cancer.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.200220. doi: 10.2967/jnumed.117.200220.
    PubMed     Text format     Abstract available

  17. RISCHPLER C, Beck TI, Okamoto S, Schlitter AM, et al
    (68)Ga-PSMA-HBED-CC uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.204677. doi: 10.2967/jnumed.117.204677.
    PubMed     Text format     Abstract available


    J Urol

  18. ATALA A
    Re: SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer.
    J Urol. 2017;198:259.
    PubMed     Text format    

  19. SIEGEL C
    Re: Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience with 101 Patients.
    J Urol. 2018;199:325.
    PubMed     Text format    

  20. SEFTEL AD
    Re: The Accuracy of Patients' Perceptions of the Risks Associated with Localised Prostate Cancer Treatments.
    J Urol. 2018;199:329.
    PubMed     Text format    

  21. TANEJA SS
    Re: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.
    J Urol. 2018;199:342-343.
    PubMed     Text format    

  22. ATALA A
    Re: mTORC1-Dependent AMD1 Regulation Sustains Polyamine Metabolism in Prostate Cancer.
    J Urol. 2018;199:344-346.
    PubMed     Text format    

  23. TANEJA SS
    Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.
    J Urol. 2017;198:255-257.
    PubMed     Text format    

  24. TANEJA SS
    Re: Change in Salvage Radiotherapy Management Based on Guidance with FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.
    J Urol. 2017;198:256-257.
    PubMed     Text format    

  25. LEE JS, Lee HS, Ha JS, Han KS, et al
    Subcutaneous fat distribution is a prognostic biomarker for men with castration-resistant prostate cancer.
    J Urol. 2018 Jan 20. pii: S0022-5347(18)30106-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  26. STONE L
    Prostate cancer: Revealing mechanisms of resistance.
    Nat Rev Urol. 2018 Jan 23. pii: nrurol.2018.7. doi: 10.1038/nrurol.2018.
    PubMed     Text format    

  27. THOMA C
    Prostate cancer: Developing CAR T cell therapy.
    Nat Rev Urol. 2018 Jan 23. pii: nrurol.2018.4. doi: 10.1038/nrurol.2018.
    PubMed     Text format    


    PLoS One

  28. HAYES AR, Brungs D, Pavlakis N
    Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0191455.
    PubMed     Text format     Abstract available


    Prostate

  29. WANG L, Kim D, Wise JTF, Shi X, et al
    p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23483.
    PubMed     Text format     Abstract available

  30. WURNSCHIMMEL C, Grande P, Moschini M, Ferrari M, et al
    Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23480.
    PubMed     Text format     Abstract available

  31. ISAACSSON VELHO P, Silberstein JL, Markowski MC, Luo J, et al
    Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23484.
    PubMed     Text format     Abstract available

  32. HUANG H, Wang Q, Du T, Lin C, et al
    Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23469.
    PubMed     Text format     Abstract available

  33. BEEBE-DIMMER JL, Zuhlke KA, Johnson AM, Liesman D, et al
    Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23464.
    PubMed     Text format     Abstract available

  34. DU Z, Lubmawa A, Gundell S, Wan P, et al
    Genetic risk of prostate cancer in ugandan men.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23481.
    PubMed     Text format     Abstract available

  35. MIKI J, Yanagisawa T, Tsuzuki S, Mori K, et al
    Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23486.
    PubMed     Text format     Abstract available


    Radiology

  36. DINH AH, Melodelima C, Souchon R, Moldovan PC, et al
    Characterization of Prostate Cancer with Gleason Score of at Least 7 by Using Quantitative Multiparametric MR Imaging: Validation of a Computer-aided Diagnosis System in Patients Referred for Prostate Biopsy.
    Radiology. 2018 Jan 22:171265. doi: 10.1148/radiol.2017171265.
    PubMed     Text format     Abstract available


    Urology

  37. CANCIAN M, Renzulli JF 2nd
    Non Metastatic Castration Resistant Prostate Cancer: a Modern Perspective.
    Urology. 2018 Jan 18. pii: S0090-4295(18)30044.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: